ONWARD Medical welcomes Vivian Riefberg to its Board as Non-Executive Director

– NETHERLANDS, Eindhoven –  ONWARD Medical N.V. (Euronext: ONWD), the medical technology company today announced the appointment of Vivian Riefberg to its Board as a Non-Executive Director, effective immediately.

“Vivian Riefberg is a distinguished expert in health care, government, and strategy. I am excited and honored to welcome her to our Board”, said CEO, Dave Marver. “Vivian brings a rich understanding of the institutions with which we will collaborate to bring our novel therapies to market, including the U.S. Veterans Health Administration. Her experience and insights will be invaluable as we work to create an entirely new therapeutic domain in neuromodulation and help people with spinal cord injury and other movement disabilities.”

Vivian Riefberg will also join the Compensation Committee.

About Vivian Riefberg

In 2020, Ms. Riefberg retired as a senior partner with McKinsey & Company, where she held a variety of senior positions, including the leader of the Public Sector Practice for the Americas and co-leader of the U.S. Health Care practice. She served on McKinsey & Company’s global board of directors and the committee evaluating and developing global partners. Ms. Riefberg is currently a Professor of Practice at the University of Virginia Darden School of Business where she holds the David C. Walentas Jefferson Scholars Chair. At Darden, Ms. Riefberg focuses on healthcare, consulting, and strategy across the private, public, and not-for-profit sectors. Her emphasis is senior executive leadership, including leading during times of uncertainty and crisis, solutions and innovations in healthcare, and women’s leadership.

Ms. Riefberg serves on the Board of Signify Health, K Health, and Lightrock, an impact investing firm, as well as of the Public Broadcasting System, Johns Hopkins Medicine, the Lorna Breen Heroes Foundation, and the National Education Equity Lab. She is also an advisory board member for the Smithsonian’s planned American Women’s History Museum. She previously served on the U.S. National Institutes of Health Clinical Center Board of Governors and the NIH Advisory Board for Clinical Research. She also served on the Board of Directors of the Partnership for a Healthier America, a nonprofit, created to mobilize efforts to solve the child obesity challenge as an outgrowth of First Lady Michelle Obama’s Let’s Move campaign.

Ms. Riefberg is a frequent speaker at various conferences including the World Economic Forum at Davos. She is also a contributor to leading industry publications on improving U.S. healthcare, addressing government productivity, and women’s leadership.

“ONWARD has the opportunity to build a very special enterprise that is both successful and impactful”, said Vivian Riefberg. “I have had the privilege to counsel many leading companies during my career. ONWARD has a chance to help people with spinal cord injury by leveraging groundbreaking science, technology, and intellectual property, fueled by a fullhearted mission.”

She holds a B.A., magna cum laude in history from Harvard-Radcliffe College and an M.B.A. with distinction from Harvard Business School.

About ONWARD Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable or external systems, is designed to deliver targeted, programmed spinal-cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

ONWARD has received three Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and leas placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It has substantial operations in Lausanne, Switzerland, and a growing U.S. presence in Boston, Massachusetts.

For more information: https://www.onwd.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.